<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03501069</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-418-1003</org_study_id>
    <secondary_id>U1111-1209-4647</secondary_id>
    <nct_id>NCT03501069</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Oral Dose of TAK-418 in Healthy Female Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-418 in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize safety and tolerability of TAK-418 in
      non-Japanese and Japanese healthy female participants when administered at single or multiple
      (once daily [QD]) oral doses.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The drug being tested in this study is called TAK-418. This study will assess the safety,
      tolerability, PK and PD of single and multiple rising doses of TAK-418 in healthy Japanese or
      non-Japanese females.

      The study will enroll approximately 48 participants in 6 cohorts and each cohort will have 8
      participants. The study will include 2 parts: single rising dose (SRD) in Cohort 1 and
      multiple rising dose (MRD) in Cohorts 2 to 6. Cohort 3 will include cerebrospinal fluid (CSF)
      collection. Participants will be randomly assigned (by chance, like flipping a coin) to one
      of the 6 cohorts.

      This two-center trial will be conducted in the United States. The overall time to participate
      in Cohort 1 of this study is approximately 105 days and 98 days in Cohort 2. Participants
      will be contacted by telephone 14 days after last dose of study drug for a follow-up
      assessment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Decision; no human safety concern; evaluating preclinical toxicology finding
  </why_stopped>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Actual">December 26, 2018</completion_date>
  <primary_completion_date type="Actual">December 26, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort 1: Number of Participants Who Experienced at Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAE)</measure>
    <time_frame>Baseline up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 2 to 5: Number of Participants Who Experienced at Least One TEAEs and SAE</measure>
    <time_frame>Baseline up to Day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1: Number of Participants With Markedly Abnormal Criteria for Clinical Laboratory Values at Least Once Postdose</measure>
    <time_frame>Baseline up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 2 to 5: Number of Participants With Markedly Abnormal Criteria for Clinical Laboratory Values at Least Once Postdose</measure>
    <time_frame>Baseline up to Day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1: Number of Participants With Markedly Abnormal Criteria for Vital Signs at Least Once Postdose</measure>
    <time_frame>Baseline up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 2 to 5: Number of Participants With Markedly Abnormal Criteria for Vital Signs at Least Once Postdose</measure>
    <time_frame>Baseline up to Day 70</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1: Number of Participants Who Meet the Markedly Abnormal Values of 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 60</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohorts 2 to 5: Number of Participants Who Meet the Markedly Abnormal Values of 12-lead ECG Parameters at Least Once Post Dose</measure>
    <time_frame>Baseline up to Day 70</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cohort 1; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-418 on Day 1</measure>
    <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cohort 2 to 5: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Over the Dosing Interval for TAK-418 on Days 1 and 10</measure>
    <time_frame>Days 1 and 10 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax: Maximum Observed Plasma Concentration for TAK-418</measure>
    <time_frame>Cohort 1: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose; Cohorts 2 to 5: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax: Time to Reach the Cmax for TAK-418</measure>
    <time_frame>Cohort 1: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose; Cohorts 2 to 5: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-418 120 milligram (mg) or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period A followed by a minimum of 14 days of washout period, followed by TAK-418 160 mg or TAK-418 matching placebo, capsule, orally, once on Day 1 of Period B. The actual TAK-418 dose for Period B will be determined based on safety, tolerability, and PK data available from the previous dose in Period A.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Japanese Cohort 2: TAK-418 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Japanese Cohort 3: TAK-418 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 3 will be determined based on safety, tolerability, and PK data available from the previous doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Japanese Cohort 4: TAK-418 60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-418 60 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 4 will be determined based on safety, tolerability, and PK data available from the previous doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort 5: TAK-418 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-418 20 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 5 will be determined based on safety, tolerability, and PK data available from the previous doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japanese Cohort 6: TAK-418 40 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TAK-418 40 mg or TAK-418 matching placebo, capsule, orally, once daily for 10 days. The actual TAK-418 dose for Cohort 6 will be determined based on safety, tolerability, and PK data available from the previous doses.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-418</intervention_name>
    <description>TAK-418 capsules.</description>
    <arm_group_label>Japanese Cohort 5: TAK-418 20 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 6: TAK-418 40 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 2: TAK-418 20 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 3: TAK-418 40 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 4: TAK-418 60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAK-418 Matching Placebo</intervention_name>
    <description>TAK-418 matching placebo capsules.</description>
    <arm_group_label>Japanese Cohort 5: TAK-418 20 mg</arm_group_label>
    <arm_group_label>Japanese Cohort 6: TAK-418 40 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 1: TAK-418 120 mg and TAK-418 160 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 2: TAK-418 20 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 3: TAK-418 40 mg</arm_group_label>
    <arm_group_label>Non-Japanese Cohort 4: TAK-418 60 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Has a body mass index (BMI) greater than or equal to (&gt;=) 18.5 and less than or equal
             to (&lt;=) 30.0 kilogram per square meter (kg/m^2) at the Screening Visit. (Cohorts 1 to
             4 only).

          2. Is a nonsmoker who has not used tobacco- or nicotine-containing products (example,
             nicotine patch) for at least 6 months before administration of the first dose of trial
             drug or invasive procedure.

          3. The participant either is of nonchildbearing potential, OR, if of childbearing
             potential, is using a highly effective method of contraception with low user
             dependency during the entire duration of the study.

        For Cohorts 5 and 6 (Japanese participants) only:

        1. Has a BMI &gt;=18.0 and &lt;= 26.0 kg/m^2, at the Screening Visit.

        Exclusion Criteria:

          1. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C
             antibody (HCV), or human immunodeficiency virus (HIV) antibody/antigen, at Screening.

          2. Had major surgery, donated or lost 1 unit of blood (approximately 500 milliliter [mL])
             within 4 weeks before the Screening Visit.

          3. Has a history of alcohol consumption exceeding 2 standard drinks per day on average (1
             glass is approximately equivalent to beer [354 mL/12 ounces], wine [118 mL/4 ounces],
             or distilled spirits [29.5 mL/1 ounce] per day).

          4. Consumes excessive amounts, defined as greater than 6 servings (1 serving is
             approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks,
             or other caffeinated beverages per day.

          5. Has a substance abuse disorder.

          6. Has risk of suicide according to the investigator's clinical judgment per
             Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening or has made a suicide
             attempt in the 6 months before Screening.

          7. Has luteinizing hormone (LH), follicle-stimulating hormone (FSH), or estradiol levels
             that are clinically abnormal.

          8. Has a resting heart rate outside of the range of 50 to 100 beats per minute, confirmed
             on repeat testing within a maximum of 30 minutes, at the Screening Visit or Check-in
             (Day -1).

        For Cohort 3 only (includes CSF sample collection):

          1. Has had CSF collection performed within 30 days before Check-in (Day -1).

          2. Has significant vertebral deformities (scoliosis or kyphosis) that, in the opinion of
             the investigator, may interfere with the lumbar puncture procedure.

          3. Has a local infection at the puncture site.

          4. Has thrombocytopenia or other suspected bleeding tendencies noted before the
             procedure.

          5. Has developed signs and symptoms of spinal radiculopathy, including lower extremity
             pain and paresthesia.

          6. Has any focal neurological deficit that might suggest an increase in intracranial
             pressure.

          7. Has any abnormal finding on ophthalmological assessment/fundoscopy indicative of
             raised intracranial pressure (that is, optic disc swelling/edema; or [uncontrolled]
             hypertensive retinopathy).

          8. Regularly has moderate-to-severe headaches requiring analgesics.

          9. Has any bleeding abnormality or history of bleeding abnormalities.

         10. Has abnormal coagulation tests (prothrombin time [PT]/international normalized ratio
             [INR], partial thromboplastin time [PTT]) at Screening.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parexel International</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 10, 2018</study_first_submitted>
  <study_first_submitted_qc>April 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <results_first_submitted>December 13, 2019</results_first_submitted>
  <results_first_submitted_qc>June 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 16, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03501069/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/69/NCT03501069/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 2 investigative sites in the United States from 30 May 2018 to 26 December 2018.</recruitment_details>
      <pre_assignment_details>Healthy female participants were enrolled to receive TAK-418 as single rising dose (SRD) dose of 120 milligram (mg), or 160 mg (non-Japanese cohort), and/or placebo in a crossover fashion; and multiple rising dose (MRD) of 20 mg, 60 mg, 160 mg (non-Japanese cohort) or 20 mg (Japanese cohort). The study was terminated early due to business decision.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Non-Japanese Cohort 1: TAK-418 120 mg + Placebo</title>
          <description>TAK-418 120 mg capsule, orally, once on Day 1 of Period A, followed by a washout period of at least 14 days, further followed by TAK-418 120 mg placebo-matching capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="P2">
          <title>Non-Japanese Cohort 1: TAK-418 120 mg + TAK-418 160 mg</title>
          <description>TAK-418 120 mg capsule, orally, once on Day 1 of Period A, followed by a washout period of at least 14 days, further followed by TAK-418 160 mg capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="P3">
          <title>Non-Japanese Cohort 1: Placebo + TAK-418 160 mg</title>
          <description>TAK-418 160 mg placebo-matching capsule, orally, once on Day 1 of Period A, followed by a washout period of at least 14 days, further followed by TAK-418 160 mg capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="P4">
          <title>Non-Japanese Cohorts 2 to 4: Pooled Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="P5">
          <title>Japanese Cohort 5: Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="P6">
          <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
          <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="P7">
          <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
          <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="P8">
          <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
          <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="P9">
          <title>Japanese Cohort 5: TAK-418 20 mg</title>
          <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period A</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (at Least 14 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P5" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P6" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P7" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P8" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P9" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period B</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P5" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P6" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P7" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P8" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
                <participants group_id="P9" count="0">Participants other than Cohort 1 were not to continue in subsequent Periods after Period A.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Non-Japanese Cohort 1: TAK-418 120 mg + Placebo</title>
          <description>TAK-418 120 mg capsule, orally, once on Day 1 of Period A, followed by a washout period of at least 14 days, further followed by TAK-418 120 mg placebo-matching capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="B2">
          <title>Non-Japanese Cohort 1: TAK-418 120 mg + TAK-418 160 mg</title>
          <description>TAK-418 120 mg capsule, orally, once on Day 1 of Period A, followed by a washout period of at least 14 days, further followed by TAK-418 160 mg capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="B3">
          <title>Non-Japanese Cohort 1: Placebo + TAK-418 160 mg</title>
          <description>TAK-418 160 mg placebo-matching capsule, orally, once on Day 1 of Period A, followed by a washout period of at least 14 days, further followed by TAK-418 160 mg capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="B4">
          <title>Non-Japanese Cohorts 2 to 4: Pooled Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="B5">
          <title>Japanese Cohort 5: Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="B6">
          <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
          <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="B7">
          <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
          <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="B8">
          <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
          <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="B9">
          <title>Japanese Cohort 5: TAK-418 20 mg</title>
          <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="1"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="3"/>
            <count group_id="B9" value="3"/>
            <count group_id="B10" value="32"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="7.78"/>
                    <measurement group_id="B2" value="39.8" spread="11.32"/>
                    <measurement group_id="B3" value="39.0" spread="18.38"/>
                    <measurement group_id="B4" value="47.8" spread="11.78"/>
                    <measurement group_id="B5" value="49.0" spread="NA">Standard deviation was not estimable since only one participant was analyzed.</measurement>
                    <measurement group_id="B6" value="39.2" spread="12.32"/>
                    <measurement group_id="B7" value="46.7" spread="10.93"/>
                    <measurement group_id="B8" value="43.3" spread="4.04"/>
                    <measurement group_id="B9" value="50.3" spread="3.51"/>
                    <measurement group_id="B10" value="43.4" spread="10.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.050" spread="9.8288"/>
                    <measurement group_id="B2" value="67.875" spread="5.5506"/>
                    <measurement group_id="B3" value="66.250" spread="13.7886"/>
                    <measurement group_id="B4" value="70.60" spread="7.090"/>
                    <measurement group_id="B5" value="67.90" spread="NA">Standard deviation was not estimable since only one participant was analyzed.</measurement>
                    <measurement group_id="B6" value="66.60" spread="6.690"/>
                    <measurement group_id="B7" value="70.22" spread="9.100"/>
                    <measurement group_id="B8" value="78.27" spread="5.848"/>
                    <measurement group_id="B9" value="49.60" spread="3.857"/>
                    <measurement group_id="B10" value="67.859" spread="9.4141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter (cm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.00" spread="5.657"/>
                    <measurement group_id="B2" value="161.00" spread="4.243"/>
                    <measurement group_id="B3" value="166.50" spread="6.364"/>
                    <measurement group_id="B4" value="162.8" spread="7.85"/>
                    <measurement group_id="B5" value="167.0" spread="NA">Standard deviation was not estimable since only one participant was analyzed.</measurement>
                    <measurement group_id="B6" value="164.7" spread="6.47"/>
                    <measurement group_id="B7" value="163.0" spread="8.15"/>
                    <measurement group_id="B8" value="172.3" spread="7.23"/>
                    <measurement group_id="B9" value="154.7" spread="2.52"/>
                    <measurement group_id="B10" value="164.09" spread="7.485"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.90" spread="4.808"/>
                    <measurement group_id="B2" value="26.23" spread="2.636"/>
                    <measurement group_id="B3" value="23.75" spread="3.182"/>
                    <measurement group_id="B4" value="26.62" spread="1.599"/>
                    <measurement group_id="B5" value="24.30" spread="NA">Standard deviation was not estimable since only one participant was analyzed.</measurement>
                    <measurement group_id="B6" value="24.53" spread="1.401"/>
                    <measurement group_id="B7" value="26.42" spread="2.872"/>
                    <measurement group_id="B8" value="26.47" spread="3.202"/>
                    <measurement group_id="B9" value="20.77" spread="1.553"/>
                    <measurement group_id="B10" value="25.16" spread="2.775"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1: Number of Participants Who Experienced at Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAE)</title>
        <time_frame>Baseline up to Day 60</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 1; Period A: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 1; Period B: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period B.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
            <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Number of Participants Who Experienced at Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAE)</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohorts 2 to 5: Number of Participants Who Experienced at Least One TEAEs and SAE</title>
        <time_frame>Baseline up to Day 70</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohorts 2 to 4: Pooled Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 5: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
            <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 5: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 to 5: Number of Participants Who Experienced at Least One TEAEs and SAE</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1: Number of Participants With Markedly Abnormal Criteria for Clinical Laboratory Values at Least Once Postdose</title>
        <time_frame>Baseline up to Day 60</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 1; Period A: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 1; Period B: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period B.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
            <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Number of Participants With Markedly Abnormal Criteria for Clinical Laboratory Values at Least Once Postdose</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohorts 2 to 5: Number of Participants With Markedly Abnormal Criteria for Clinical Laboratory Values at Least Once Postdose</title>
        <time_frame>Baseline up to Day 70</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohorts 2 to 4: Pooled Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 5: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
            <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 5: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 to 5: Number of Participants With Markedly Abnormal Criteria for Clinical Laboratory Values at Least Once Postdose</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1: Number of Participants With Markedly Abnormal Criteria for Vital Signs at Least Once Postdose</title>
        <time_frame>Baseline up to Day 60</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 1; Period A: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 1; Period B: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period B.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
            <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Number of Participants With Markedly Abnormal Criteria for Vital Signs at Least Once Postdose</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pulse Rate less than (&lt;) 50 beats per minute (bpm)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature &lt;35.6 Celsius (C)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohorts 2 to 5: Number of Participants With Markedly Abnormal Criteria for Vital Signs at Least Once Postdose</title>
        <time_frame>Baseline up to Day 70</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohorts 2 to 4: Pooled Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 5: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
            <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 5: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 to 5: Number of Participants With Markedly Abnormal Criteria for Vital Signs at Least Once Postdose</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic Blood Pressure &lt;50 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulse Rate greater than (&gt;) 120 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic Blood Pressure &lt;85 mmHg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1: Number of Participants Who Meet the Markedly Abnormal Values of 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose</title>
        <time_frame>Baseline up to Day 60</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 1; Period A: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 1; Period B: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period B.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
            <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1: Number of Participants Who Meet the Markedly Abnormal Values of 12-lead Electrocardiogram (ECG) Parameters at Least Once Post Dose</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ECG Mean Heart Rate &lt;50 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT Interval &gt;=460 millisecond (msec)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohorts 2 to 5: Number of Participants Who Meet the Markedly Abnormal Values of 12-lead ECG Parameters at Least Once Post Dose</title>
        <time_frame>Baseline up to Day 70</time_frame>
        <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohorts 2 to 4: Pooled Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Japanese Cohort 5: Placebo</title>
            <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
            <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 5: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohorts 2 to 5: Number of Participants Who Meet the Markedly Abnormal Values of 12-lead ECG Parameters at Least Once Post Dose</title>
          <population>The safety set included all randomized participants who received at least 1 dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 1; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-418 on Day 1</title>
        <time_frame>Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose</time_frame>
        <population>The pharmacokinetic (PK) set included all participants from the safety set who had at least 1 measurable post dose plasma or cerebrospinal fluid (CSF) concentration or amount of drug in urine of TAK-418F.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
            <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1; AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-418 on Day 1</title>
          <population>The pharmacokinetic (PK) set included all participants from the safety set who had at least 1 measurable post dose plasma or cerebrospinal fluid (CSF) concentration or amount of drug in urine of TAK-418F.</population>
          <units>hour*nanogram per milliliter (hr*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3761.2" spread="20.8"/>
                    <measurement group_id="O2" value="4229.0" spread="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cohort 2 to 5: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Over the Dosing Interval for TAK-418 on Days 1 and 10</title>
        <time_frame>Days 1 and 10 pre-dose and at multiple time points (up to 24 hours) post-dose</time_frame>
        <population>The PK set included all participants from the safety set who had at least 1 measurable post dose plasma or CSF concentration or amount of drug in urine of TAK-418F.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
            <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Japanese Cohort 5: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 2 to 5: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to 24 Over the Dosing Interval for TAK-418 on Days 1 and 10</title>
          <population>The PK set included all participants from the safety set who had at least 1 measurable post dose plasma or CSF concentration or amount of drug in urine of TAK-418F.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503.3" spread="165.71"/>
                    <measurement group_id="O2" value="1445.5" spread="353.26"/>
                    <measurement group_id="O3" value="3747.3" spread="239.53"/>
                    <measurement group_id="O4" value="610.3" spread="87.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668.2" spread="228.83"/>
                    <measurement group_id="O2" value="1660.5" spread="421.77"/>
                    <measurement group_id="O3" value="4058.3" spread="249.49"/>
                    <measurement group_id="O4" value="677.3" spread="73.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax: Maximum Observed Plasma Concentration for TAK-418</title>
        <time_frame>Cohort 1: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose; Cohorts 2 to 5: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants from the safety set who had at least 1 measurable post dose plasma or CSF concentration or amount of drug in urine of TAK-418F. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
            <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
            <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 5: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax: Maximum Observed Plasma Concentration for TAK-418</title>
          <population>The PK set included all participants from the safety set who had at least 1 measurable post dose plasma or CSF concentration or amount of drug in urine of TAK-418F. PK-evaluable population where data at specified time points was available.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="714.7" spread="21.6"/>
                    <measurement group_id="O2" value="750.3" spread="40.3"/>
                    <measurement group_id="O3" value="81.1" spread="35.8"/>
                    <measurement group_id="O4" value="270.8" spread="21.6"/>
                    <measurement group_id="O5" value="657.8" spread="33.0"/>
                    <measurement group_id="O6" value="154.5" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="113.4" spread="30.8"/>
                    <measurement group_id="O4" value="303.4" spread="17.6"/>
                    <measurement group_id="O5" value="692.4" spread="15.4"/>
                    <measurement group_id="O6" value="171.1" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax: Time to Reach the Cmax for TAK-418</title>
        <time_frame>Cohort 1: Day 1 pre-dose and at multiple time points (up to 72 hours) post-dose; Cohorts 2 to 5: Days 1 and 10 pre-dose and at multiple time points (up to 48 hours) post-dose</time_frame>
        <population>The PK set included all participants from the safety set who had at least 1 measurable post dose plasma or CSF concentration or amount of drug in urine of TAK-418F. PK-evaluable population where data at specified time points was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
            <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
          </group>
          <group group_id="O2">
            <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
          </group>
          <group group_id="O3">
            <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O4">
            <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
            <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O5">
            <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
            <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
          </group>
          <group group_id="O6">
            <title>Japanese Cohort 5: TAK-418 20 mg</title>
            <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax: Time to Reach the Cmax for TAK-418</title>
          <population>The PK set included all participants from the safety set who had at least 1 measurable post dose plasma or CSF concentration or amount of drug in urine of TAK-418F. PK-evaluable population where data at specified time points was available.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.500" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O2" value="1.250" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.750" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.500" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.500" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O6" value="1.000" lower_limit="0.50" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.260" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="1.250" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O5" value="1.000" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O6" value="1.000" lower_limit="1.00" upper_limit="1.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>TEAEs are adverse events (AEs) that started after the first dose of study drug and no more than 30 days after the last dose of study drug (up to Day 60 in Cohort 1 and Day 70 in Cohorts 2 to 5)</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Non-Japanese Cohort 1; Period A: Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period A.</description>
        </group>
        <group group_id="E2">
          <title>Non-Japanese Cohort 1; Period B: Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="E3">
          <title>Non-Japanese Cohort 1: TAK 418 120 mg</title>
          <description>TAK-418 120 mg, capsule, orally, once on Day 1 of Period A.</description>
        </group>
        <group group_id="E4">
          <title>Non-Japanese Cohort 1: TAK 418 160 mg</title>
          <description>TAK-418 160 mg, capsule, orally, once on Day 1 of Period B.</description>
        </group>
        <group group_id="E5">
          <title>Non-Japanese Cohorts 2 to 4: Pooled Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="E6">
          <title>Japanese Cohort 5: Placebo</title>
          <description>TAK-418 placebo-matching capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="E7">
          <title>Non-Japanese Cohort 2: TAK-418 20 mg</title>
          <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="E8">
          <title>Non-Japanese Cohort 3: TAK-418 60 mg</title>
          <description>TAK-418 60 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="E9">
          <title>Non-Japanese Cohort 4: TAK-418 160 mg</title>
          <description>TAK-418 160 mg, capsule, orally, once daily for 10 days.</description>
        </group>
        <group group_id="E10">
          <title>Japanese Cohort 5: TAK-418 20 mg</title>
          <description>TAK-418 20 mg, capsule, orally, once daily for 10 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Procedural headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Food aversion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypervigilance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Research Organization shall not publish any articles or papers nor make any presentations, nor assist any other person in publishing any articles or papers or in making any presentations relating or referring to the Study or any results, data or insights from or any data, information or materials obtained or generated in the performance of its obligations without the prior written consent of Takeda, which consent may be granted or withheld in Takeda’s sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

